Brainkind has announced the appointment of Chris Askew as interim CEO, effective 23 March 2026.
Askew brings extensive experience of leading national charities and membership organisations.
His previous roles include Chief Executive of Diabetes UK, Chief Executive of Breakthrough Breast Cancer, and senior leadership positions at the Royal College of General Practitioners, and the General Pharmaceutical Council.
He is a values-led leader with a strong commitment to supporting people with neurological conditions and with a personal connection to Brainkind’s mission through his years as a trustee at Action for A-T.
Chris Askew
Kathryn Greenberg, Chair of the Board of Trustees, said: “We are delighted to welcome Chris to Brainkind.
“He brings significant experience of leading complex organisations, and a strong commitment to the people and communities we serve.
“Chris will work closely with the Board and the Executive Leadership Team to build on our strong foundations, strengthen our financial sustainability, and support delivery of our strategic priorities as we look ahead with confidence.”
Askew will provide steady leadership while the Board of Trustees undertakes a careful and considered search for a permanent CEO.
The recruitment process is expected to conclude by the end of May, with a new CEO joining later in 2026.
There will be no change to Brainkind’s services, strategic direction, or the ongoing commitment to delivering high-quality care and support for people with brain injuries and neurological conditions, and their families.
Askew said: “I am delighted to be joining Brainkind as Interim Chief Executive at such an important time.
“The organisation’s commitment to empowering people with brain injuries and neurological conditions to live full and meaningful lives could not be more important.
“I am excited to work alongside the dedicated team to strengthen and expand our services and to ensure that we continue to make a real difference to the lives of those who rely upon us.”
